Subgroup analysis of the association between pregnancy after breast cancer diagnosis and total mortality
| . | Comparison group . | BCPP group . | . | . | ||
|---|---|---|---|---|---|---|
| Subgroups . | Total no. . | Death no. . | Total no. . | Death no. . | HRa . | 95% CI . |
| By ER status | ||||||
| ER− | 143 | 20 | 46 | 4 | 0.38 | (0.12, 1.24) |
| ER+ | 311 | 32 | 87 | 3 | 0.23 | (0.07, 0.77) |
| No information | 460 | 17 | 116 | 5 | 0.94 | (0.31, 2.89) |
| By hormone therapy | ||||||
| No | 379 | 40 | 138 | 9 | 0.40 | (0.17, 0.91) |
| Yes | 535 | 29 | 111 | 3 | 0.46 | (0.15, 1.38) |
| By chemotherapy | ||||||
| No | 244 | 16 | 101 | 5 | 0.48 | (0.15, 1.56) |
| Yes | 670 | 53 | 148 | 7 | 0.40 | (0.18, 0.90) |
| By age at diagnosis, years | ||||||
| <30 | 241 | 25 | 96 | 4 | 0.29 | (0.10, 0.88) |
| ≥30 to <35 | 417 | 31 | 105 | 5 | 0.49 | (0.18, 1.31) |
| ≥35 | 256 | 13 | 48 | 3 | 0.44 | (0.09, 2.31) |
| By stage at diagnosis | ||||||
| I | 438 | 16 | 126 | 4 | 0.39 | (0.11, 1.41) |
| II and III | 476 | 53 | 123 | 8 | 0.37 | (0.16, 0.82) |
| By positive nodes | ||||||
| 0 | 657 | 32 | 173 | 6 | 0.62 | (0.25, 1.52) |
| 1–3 | 146 | 14 | 34 | 3 | 0.68 | (0.17, 2.66) |
| ≥4 | 65 | 20 | 20 | 2 | 0.31 | (0.07, 1.47) |
| . | Comparison group . | BCPP group . | . | . | ||
|---|---|---|---|---|---|---|
| Subgroups . | Total no. . | Death no. . | Total no. . | Death no. . | HRa . | 95% CI . |
| By ER status | ||||||
| ER− | 143 | 20 | 46 | 4 | 0.38 | (0.12, 1.24) |
| ER+ | 311 | 32 | 87 | 3 | 0.23 | (0.07, 0.77) |
| No information | 460 | 17 | 116 | 5 | 0.94 | (0.31, 2.89) |
| By hormone therapy | ||||||
| No | 379 | 40 | 138 | 9 | 0.40 | (0.17, 0.91) |
| Yes | 535 | 29 | 111 | 3 | 0.46 | (0.15, 1.38) |
| By chemotherapy | ||||||
| No | 244 | 16 | 101 | 5 | 0.48 | (0.15, 1.56) |
| Yes | 670 | 53 | 148 | 7 | 0.40 | (0.18, 0.90) |
| By age at diagnosis, years | ||||||
| <30 | 241 | 25 | 96 | 4 | 0.29 | (0.10, 0.88) |
| ≥30 to <35 | 417 | 31 | 105 | 5 | 0.49 | (0.18, 1.31) |
| ≥35 | 256 | 13 | 48 | 3 | 0.44 | (0.09, 2.31) |
| By stage at diagnosis | ||||||
| I | 438 | 16 | 126 | 4 | 0.39 | (0.11, 1.41) |
| II and III | 476 | 53 | 123 | 8 | 0.37 | (0.16, 0.82) |
| By positive nodes | ||||||
| 0 | 657 | 32 | 173 | 6 | 0.62 | (0.25, 1.52) |
| 1–3 | 146 | 14 | 34 | 3 | 0.68 | (0.17, 2.66) |
| ≥4 | 65 | 20 | 20 | 2 | 0.31 | (0.07, 1.47) |
aHazard ratios were adjusted for age and year of diagnosis, stage, nodal status, and hormone therapy, where appropriate.
Abbreviations: BCPP, patients with breast cancer with a pregnancy after cancer diagnosis; CI, confidence interval; ER, estrogen receptor; HR, hazard ratio.
Subgroup analysis of the association between pregnancy after breast cancer diagnosis and total mortality
| . | Comparison group . | BCPP group . | . | . | ||
|---|---|---|---|---|---|---|
| Subgroups . | Total no. . | Death no. . | Total no. . | Death no. . | HRa . | 95% CI . |
| By ER status | ||||||
| ER− | 143 | 20 | 46 | 4 | 0.38 | (0.12, 1.24) |
| ER+ | 311 | 32 | 87 | 3 | 0.23 | (0.07, 0.77) |
| No information | 460 | 17 | 116 | 5 | 0.94 | (0.31, 2.89) |
| By hormone therapy | ||||||
| No | 379 | 40 | 138 | 9 | 0.40 | (0.17, 0.91) |
| Yes | 535 | 29 | 111 | 3 | 0.46 | (0.15, 1.38) |
| By chemotherapy | ||||||
| No | 244 | 16 | 101 | 5 | 0.48 | (0.15, 1.56) |
| Yes | 670 | 53 | 148 | 7 | 0.40 | (0.18, 0.90) |
| By age at diagnosis, years | ||||||
| <30 | 241 | 25 | 96 | 4 | 0.29 | (0.10, 0.88) |
| ≥30 to <35 | 417 | 31 | 105 | 5 | 0.49 | (0.18, 1.31) |
| ≥35 | 256 | 13 | 48 | 3 | 0.44 | (0.09, 2.31) |
| By stage at diagnosis | ||||||
| I | 438 | 16 | 126 | 4 | 0.39 | (0.11, 1.41) |
| II and III | 476 | 53 | 123 | 8 | 0.37 | (0.16, 0.82) |
| By positive nodes | ||||||
| 0 | 657 | 32 | 173 | 6 | 0.62 | (0.25, 1.52) |
| 1–3 | 146 | 14 | 34 | 3 | 0.68 | (0.17, 2.66) |
| ≥4 | 65 | 20 | 20 | 2 | 0.31 | (0.07, 1.47) |
| . | Comparison group . | BCPP group . | . | . | ||
|---|---|---|---|---|---|---|
| Subgroups . | Total no. . | Death no. . | Total no. . | Death no. . | HRa . | 95% CI . |
| By ER status | ||||||
| ER− | 143 | 20 | 46 | 4 | 0.38 | (0.12, 1.24) |
| ER+ | 311 | 32 | 87 | 3 | 0.23 | (0.07, 0.77) |
| No information | 460 | 17 | 116 | 5 | 0.94 | (0.31, 2.89) |
| By hormone therapy | ||||||
| No | 379 | 40 | 138 | 9 | 0.40 | (0.17, 0.91) |
| Yes | 535 | 29 | 111 | 3 | 0.46 | (0.15, 1.38) |
| By chemotherapy | ||||||
| No | 244 | 16 | 101 | 5 | 0.48 | (0.15, 1.56) |
| Yes | 670 | 53 | 148 | 7 | 0.40 | (0.18, 0.90) |
| By age at diagnosis, years | ||||||
| <30 | 241 | 25 | 96 | 4 | 0.29 | (0.10, 0.88) |
| ≥30 to <35 | 417 | 31 | 105 | 5 | 0.49 | (0.18, 1.31) |
| ≥35 | 256 | 13 | 48 | 3 | 0.44 | (0.09, 2.31) |
| By stage at diagnosis | ||||||
| I | 438 | 16 | 126 | 4 | 0.39 | (0.11, 1.41) |
| II and III | 476 | 53 | 123 | 8 | 0.37 | (0.16, 0.82) |
| By positive nodes | ||||||
| 0 | 657 | 32 | 173 | 6 | 0.62 | (0.25, 1.52) |
| 1–3 | 146 | 14 | 34 | 3 | 0.68 | (0.17, 2.66) |
| ≥4 | 65 | 20 | 20 | 2 | 0.31 | (0.07, 1.47) |
aHazard ratios were adjusted for age and year of diagnosis, stage, nodal status, and hormone therapy, where appropriate.
Abbreviations: BCPP, patients with breast cancer with a pregnancy after cancer diagnosis; CI, confidence interval; ER, estrogen receptor; HR, hazard ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
